Insulet
PODD
133.17
-4.06
-2.96%
Insulet
US · PODD
#1561 by market cap
Listed 1970
133.17
-4.06
-2.96%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
Quant vs Street three independent views, side by side
StockVane factor grade
A-
Momentum strategy signal
Strong Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Deteriorating
2 10
■ Upgrades■ Downgrades
- 2 upgrades vs 10 downgrades among tracked analyst rating changes.
- Most recent: J.P. Morgan moved from Buy to Hold on 2026-11-05.
Analyst consensus 14 analysts
Buy
Avg price target 177.23 +33.1%
Price target rangecurrent 133.17
Low160.00
Avg177.23
High200.00
Buy 43%
Hold 57%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-09 | Truist Financial | -- | Hold | 160.00 |
| 2026-11-06 | Barclays | -- | Hold | 165.00 |
| 2026-11-05 | Wells Fargo | -- | Hold | 172.00 |
| 2026-11-05 | Bernstein | -- | Buy | 200.00 |
| 2026-11-05 | UBS | -- | Hold | 171.00 |
| 2026-11-05 | Stifel | -- | Buy | 180.00 |
| 2026-11-05 | Citi | -- | Hold | 170.00 |
| 2026-11-05 | Leerink Partners | -- | Hold | 167.00 |
| 2026-11-05 | J.P. Morgan | -- | Hold | 170.00 |
| 2026-11-04 | CCORF | -- | Buy | 179.00 |
| 2026-11-04 | BTIG | -- | Hold | -- |
| 2026-11-04 | Baird | -- | Buy | 200.00 |
| 2026-11-04 | RBC Capital | -- | Buy | 180.00 |
| 2026-10-21 | Citi | -- | Hold | 150.00 |
| 2026-10-12 | Jefferies | -- | Buy | 190.00 |
| 2026-10-12 | Leerink Partners | -- | Hold | 143.00 |
| 2026-10-07 | Barclays | -- | Hold | 150.00 |
| 2026-10-01 | RBC Capital | -- | Buy | 160.00 |
| 2026-09-30 | Citi | -- | Hold | -- |
| 2026-08-13 | Citi | -- | Hold | 150.00 |
| 2026-08-12 | UBS | -- | Hold | 150.00 |
| 2026-08-06 | TD Cowen | -- | Hold | 144.00 |
| 2026-08-06 | CCORF | -- | Buy | 179.00 |
| 2026-08-06 | Bernstein | -- | Buy | 175.00 |
| 2026-08-06 | UBS | -- | Hold | 150.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-11-05 | J.P. Morgan | Buy → Hold | 170.00 |
| 2026-11-05 | Wells Fargo | Buy → Hold | 172.00 |
| 2026-10-07 | Barclays | Sell → Hold | 150.00 |
| 2026-08-06 | Leerink Partners | Buy → Hold | 145.00 |
| 2026-08-06 | Truist Financial | Buy → Hold | 153.00 |
| 2026-08-06 | BTIG | Buy → Hold | -- |
| 2026-08-05 | Oppenheimer | Buy → Hold | -- |
| 2026-07-28 | UBS | Buy → Hold | 174.00 |
| 2026-04-07 | Citi | Buy → Hold | 230.00 |
| 2026-01-27 | TD Cowen | Buy → Hold | 294.00 |
| 2026-01-09 | Barclays | Hold → Sell | 274.00 |
| 2025-11-18 | UBS | Hold → Buy | 400.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-04 | -- | ±11.66% | +6.56% (in line) |
| 2026/Q2 | 2026-08-05 | -- | ±11.33% | -20.12% (beat) |
| 2026/Q1 | 2026-05-06 | -- | ±9.55% | -9.70% (beat) |
| 2025/Q4 | 2026-02-18 | -- | ±7.65% | +4.76% (in line) |
| 2025/Q3 | 2025-11-06 | -- | ±10.15% | +2.85% (in line) |
| 2025/Q2 | 2025-08-07 | -- | ±9.93% | +9.47% (in line) |
| 2025/Q1 | 2025-05-08 | After close | ±7.76% | +20.88% (beat) |
| 2024/Q4 | 2025-02-20 | After close | ±11.18% | -1.90% (in line) |
| 2024/Q3 | 2024-11-07 | After close | ±11.57% | +9.40% (in line) |
| 2024/Q2 | 2024-08-08 | After close | ±11.28% | -8.81% (in line) |
| 2024/Q1 | 2024-05-09 | After close | ±12.72% | -6.55% (in line) |
| 2023/Q4 | 2024-02-22 | After close | ±13.27% | -6.56% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 20:01:08 · For reference only, not investment advice and not tailored to your situation.
Insulet discussion 0 comments